Adial Pharmaceuticals Inc. has announced that it received a notice from The Nasdaq Stock Market on May 23, 2025, indicating non-compliance with Nasdaq Listing Rule 5550(b)(1). The company's stockholders' equity was reported at $2,126,662 as of March 31, 2025, falling short of the minimum requirement of $2,500,000. Currently, the notification does not affect Adial's listing on the Nasdaq Capital Market, provided they adhere to other listing requirements. The company has until July 7, 2025, to submit a Compliance Plan to regain compliance. If accepted, Nasdaq may grant an extension of up to 180 days. Failure to comply could lead to a hearing to appeal any potential suspension or delisting.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.